- Home
- IMMR vs AGEN Comparison
IMMR vs AGEN Comparison
Compare IMMR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMR
- AGEN
- Stock Information
- Founded
- IMMR 1993
- AGEN 1994
- Country
- IMMR United States
- AGEN United States
- Employees
- IMMR N/A
- AGEN N/A
- Industry
- IMMR Computer peripheral equipment
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMMR Technology
- AGEN Health Care
- Exchange
- IMMR Nasdaq
- AGEN Nasdaq
- Market Cap
- IMMR 284.5M
- AGEN 97.7M
- IPO Year
- IMMR 1999
- AGEN 2000
- Fundamental
- Price
- IMMR $8.33
- AGEN $4.49
- Analyst Decision
- IMMR Strong Buy
- AGEN Buy
- Analyst Count
- IMMR 1
- AGEN 3
- Target Price
- IMMR $13.50
- AGEN $10.00
- AVG Volume (30 Days)
- IMMR 512.0K
- AGEN 339.2K
- Earning Date
- IMMR 11-11-2024
- AGEN 11-05-2024
- Dividend Yield
- IMMR 2.14%
- AGEN N/A
- EPS Growth
- IMMR 57.07
- AGEN N/A
- EPS
- IMMR 2.04
- AGEN N/A
- Revenue
- IMMR $163,133,000.00
- AGEN $159,630,000.00
- Revenue This Year
- IMMR $988.71
- AGEN N/A
- Revenue Next Year
- IMMR $88.38
- AGEN $0.04
- P/E Ratio
- IMMR $4.15
- AGEN N/A
- Revenue Growth
- IMMR 338.21
- AGEN 60.67
- 52 Week Low
- IMMR $5.94
- AGEN $4.18
- 52 Week High
- IMMR $13.94
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- IMMR 43.20
- AGEN 40.14
- Support Level
- IMMR $8.36
- AGEN $4.50
- Resistance Level
- IMMR $8.60
- AGEN $4.78
- Average True Range (ATR)
- IMMR 0.23
- AGEN 0.28
- MACD
- IMMR 0.03
- AGEN 0.02
- Stochastic Oscillator
- IMMR 32.50
- AGEN 42.47
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).